Iambic Enters into Collaboration with Takeda for AI-Based Small Molecule Drug Discovery
Tuesday, February 10, 2026
Iambic has entered into a multi-year technology and discovery collaboration with Takeda to support the development of small-molecule drug programmes using artificial intelligence.
Under the agreement, Iambic’s AI-based drug discovery platform will be used to advance selected high-priority programmes within Takeda’s Oncology and Gastrointestinal and Inflammation therapeutic areas. Takeda will also gain access to NeuralPLexer, Iambic’s protein–ligand structure prediction model, to support molecular design and optimisation.
The collaboration is intended to accelerate early drug discovery by improving candidate selection and supporting faster progression from early research stages to investigational new drug (IND) development. The partnership combines Iambic’s computational models with its automated and high-throughput laboratory capabilities, enabling rapid design, synthesis, testing and analysis of potential drug candidates.
As part of the agreement, Iambic will receive upfront payments, research funding and technology access fees. The company is also eligible for performance-based milestone payments that may exceed USD 1.7 billion, along with royalties on future product sales arising from the collaboration.
The partnership will make use of Iambic’s integrated AI discovery platform, which is designed to address complex drug design challenges. The platform combines predictive models for molecular structure and biological activity with automated laboratory systems, allowing for frequent and efficient design-make-test cycles.
This approach supports the exploration of new chemical structures and the optimisation of multiple drug properties to improve the likelihood of clinical success.
Source: iambic.ai
